摘要:
PROBLEM TO BE SOLVED: To provide a method suitable for a practically commercial scale process, including no expensive step, as a method for synthesizing (S)-7-hydroxy-3-(4'-hydroxyphenyl)-4-methyl-2-ä4"-[2'''-(1-piperidino)-ethoxy]phenyl}-2H-benzopyrane 4',7-bistrimethyl acetate. SOLUTION: A short practical commercial process for the efficient enantioselective synthesis of the non-steroidal antiestrogen of formula (I) or (XIV) or a pharmaceutically acceptable salt thereof is provided. The process comprises a step of reacting a compound of formula (IV) with a compound represented by formula (VII). COPYRIGHT: (C)2005,JPO&NCIPI
摘要:
NEW MATERIAL:A compound shown by the formula I [R -R are H, OH, or -OQ (Q is group shown by the formula II, or formula III); with the proviso that at least two of R -R are -OQ]. EXAMPLE:3,5,7,3,',4'-Pentahydroxyflavone-tris(1,2-naphthoqui-no-ne-2-d iazido-5-sul fonate). USE:The compound responds to radiation, is blended with an alkali-soluble resin such as novolak resin or vinyphenolic resin, etc., and useful as a positive photoresist composition. It has improved sensitivity, short exposure time, and is not only useful for VLSI but also useful for producing common IC, for producing masks, and for offset printing. PREPARATION:A flavone or isoflavone compound shown by the formula IV (R '-R ' are H, or OH; number of OH is 2-7) is reacted with a quinonediazide sulfonyl chloride shown by the formula Q-Cl in a solvent such as dioxane, etc., in the presence of triethylamine, to give a compound shown by the formula I.
摘要:
PURPOSE:A carcinostatic agent having extremely low toxicity and improved carcinostatic activity, comprising a specific compound such as chalcone, flavanone, etc. CONSTITUTION:A carcinostatic agent containing a compound selected from chalcone, dihydrochalcone, flavanone, isoflavanone, rotenoid, isoflavan, isoflavene, pterocarpan, coumestan, 3-arylcoumarin derivative, and dimethylmelannein as an active ingredient. The compound was found newly to have differentiation and introduction activity against animal tumor cells. An amount of the compound in a pharmaceutical preparation is preferably 0.3-15wt%, a daily dose is 0.01- 100mg per kg weight of adult in case of oral administration, the upper limit is 50mg, especially 10mg, and the upper limit of parenteral administration is 10mg, especially 2mg.